When does the fingolimod (Gilenya) patent expire?
The exact expiration date depends on the jurisdiction and on which specific patent is being considered (drug substance, formulation, or method-of-use). Publicly discussed exclusivity timelines for fingolimod tend to center on U.S. and European patents for Gilenya, with later entries for different dosing forms and use cases.
Which patents cover fingolimod and how are they different?
Fingolimod’s IP coverage typically comes in layers:
- Patents covering the active ingredient (the chemical compound).
- Patents covering specific pharmaceutical compositions or formulations (how the drug is made or delivered).
- Patents covering particular methods of use (for example, treatment protocols or specific patient subsets).
Different patent layers can expire at different times, which is why generics or “new” branded products may enter some markets earlier than others.
Can generics or biosimilars come out before the “main” patent ends?
Yes. Even if one key patent is still in force, competitors may enter with products that avoid infringement by:
- Using a different claim scope (for example, a route, dosage form, or formulation that falls outside certain claims).
- Launching only after a specific patent or regulatory exclusivity window expires.
- Challenging patents through litigation (so-market timing depends on court outcomes as much as on the calendar).
Why do fingolimod patent disputes matter for drug pricing and availability?
Patent status affects:
- When lower-cost generic competition can start.
- Whether brand pricing remains protected in a market.
- How quickly prescribers and health systems can switch options, especially if payers restrict coverage until generic availability.
Who made fingolimod (and what products are relevant to patents)?
Fingolimod is marketed as Gilenya. Patent questions usually reference Gilenya’s compound and related IP, plus later patents for dosing and lifecycle management (such as new formulations or label expansions), depending on the country.
What happens to patent protection if a patent is invalidated?
If a court invalidates a fingolimod patent (or narrows it so competitors no longer infringe), that can accelerate generic or alternative market entry in that jurisdiction, even if other patents remain in force.
How do I look up the exact fingolimod patent expiration date for a country?
To get the correct date, you need:
- The country (e.g., U.S., UK, Germany, EU member state).
- The specific patent number or the product authorization reference.
- Whether you’re asking about patent expiry or regulatory exclusivity (which can be different).
If you tell me the country (and whether you mean “patent expiry” or “regulatory exclusivity”), I can narrow the answer to the relevant expiration timeline and the likely controlling patents.
Sources
No sources were provided in the prompt, so I can’t cite specific fingolimod patent expiration dates or patent numbers here.